---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040653"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:27:43.084751+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 4DMT reports Q2 net loss $29.6M; cash $310M; positive interim data for 4D-150 and 4D-710; Astellas deal

## Summary
- Q2 net loss $29.6M ($28.1M prior year); R&D expense $23.6M; cash $310M as of June 30, 2023.
- Cash includes $129M net public offering proceeds and $20M Astellas upfront; expected to fund into H1 2026.
- Positive interim 4D-150 data: 100% reduction in anti-VEGF injections at high dose; durable response >1 year.
- Phase 2 Dose Expansion of 4D-150 completed enrollment of 50 patients nearly two quarters ahead of schedule.
- License with Astellas: $20M upfront, up to $942.5M milestones plus royalties for R100 vector in rare ophthalmic diseases.

## SEC filing metadata
- accession: 0000950170-23-040653
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017023040653/0000950170-23-040653-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017023040653/fdmt-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040653
- JSON: https://secwatch.observer/filing/0000950170-23-040653.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040653.txt

## Key facts
- Earnings Releases
  4D Molecular Therapeutics, Inc. reported financial results for three months ended June 30, 2023.
  - Period: three months ended June 30, 2023
  - Result: reported results
  source text: On August 9, 2023, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000095017023040653/0000950170-23-040653-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.